EANM’08 – CME Session III
Drug Development / Radiopharmacy
October 12, 2008, 14:30 – 16:00
Therapeutic Radiopharmaceuticals: from Bench to Bedside
Moderator: P. Elsinga (Groningen)
Co-Moderator: C. Halldin (Stockholm)
|O. Boerman (Nijmegen):
Synthesis and Selection of Radiotherapeutics
|S. Mather (London):
Pre-Clinical Studies in Animal Models
|R. Valkema (Rotterdam):
- To understand the properties of therapeutic radionuclides and the synthesis of radiotherapeutics.
- To have an overview of relevant animal models for efficient evaluation and validation of newly developed radiotherapeutics.
- To know the clinical indications of radiotherapeutics, and be aware of future developments, possibilities and challenges.
Therapeutic radiopharmaceuticals have gained a growing interest during the last decade and new clinical applications have emerged. Dissemination of these treatment modalities will be of benefit for several patient groups.
This session will first discuss aspects of design and synthesis of radiopharmaceuticals for therapy including selection criteria, binding properties, metabolism and the importance of selecting the most appropriate radionuclide. The second presentation deals with the properties, selection and use of animal models for evaluation and validation of newly developed radiotherapeutics .
In the third part, clinical applications will be described in which radionuclide therapy has been successful and of benefit for the patient. Moreover future developments, possibilities and challenges will be discussed.
Radionuclide therapy, animal models